Evercore ISI Shines Some Light on Rocket Pharmaceuticals (RCKT) Regulatory Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. GNK
3. NVDA
4. AZN
5. SPCX
6. FNGR
7. PLUR
8. EYPT
9. HIVE
10. GSAT

Go back to Evercore ISI Shines Some Light on Rocket Pharmaceuticals (RCKT) Regulatory Update

Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting

December 22, 2022 6:00 AM EST

Based on ongoing FDA discussion, Rocket to pursue a biomarker-based composite endpoint for a single arm, open-label pivotal trial with a natural history comparator

Initiation of initial component of global study anticipated in 1H23

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a... More